Fundamental Research Division
The DRF at the CEA assemble approximately 6,000 scientists since January 2016.
The DSV places its technological environment and equipment at the service of an assertive innovation policy that is open to industry, offering easy access to its own equipment. It participates in the scientific interest association IBiSA (Infrastructures in Biology, Health and Agriculture). This group supports, finances and evaluates the main national research platforms in biology, giving them visibility and a system of quality management adapted to the requirements of industry. Many of these platforms are implicated in the structuration and funding dispositive of the Investissements d’Avenir Program: National Infrastructures in biology and health. The DSV is directly involved in eight of them (France Génomique, FLI, NeurATRIS, IDMIT, PROFI, FRISBI, MetaboHub, IFB).
The DSV pays great attention to the protection of its intellectual property and holds a portfolio of 164 active patents that were the subject of 46 license agreements as of the end of 2014.
The DSV fosters research partnerships with industry. Collaboration through services is possible, but the sharing of expertise in joint research programs is the preferred mode. DSV teams are heavily engaged in research agreements, on either a bilateral basis or as a consortium involving several partners, often in the framework of projects supported by national or European funding. The partners of the DSV are just as much large industrial groups (AREVA, BioMérieux, EDF, L’Oréal, Pierre Fabre, Sanofi, Servier, Siemens, Total Énergies Nouvelles) as they are small and medium enterprises (Anova Plus, Bertin Pharma, Fermentalg, Guerbet).Collaboration in the long run can be done in the form of hosting private teams in the CEA premises.
The DSV has enabled the creation of approximately twenty startups, primarily in the biomedical field. The technological spin-off is an effective way of maturation and development of patents at the CEA, with licensed companies eligible for efficient technical and commercial accompaniment.
Some companies that have benefited from the spin-off process at the CEA:
The objective of translational research is to promote the coupling between basic, preclinical, clinical and pharmaceutical research. The facilitated interaction between researchers from these different specialties can significantly accelerate the development of therapeutic innovations. The DSV applies this approach in the fields of neuropathology and infectious diseases. Its teams have, for example, contributed to the clinical validation of gene therapy for Parkinson’s disease. In line with the European roadmap EATRIS, the DSV coordinates two national infrastructures for translational research: NeurATRIS (for the neurosciences) and IDMIT (for experimental models and vaccine technologies).
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.